ERBB2 and breast carcinoma: Interesting is the research of Loo et al. [26] and Fekrazad et al. [27] which demonstrated that the modification of GNSs with anti-Human Epidermal Growth Factor Receptor (HER)-2 antibodies such as Herceptin® (Genentech, South San Francisco, CA, USA) allows selective GNS accumulation in breast cancer cells.